secwatch.observer — SEC 8-K summary
======================================

Issuer:     INNOVATE Corp. (VATE)
CIK:        0001006837
Form:       8-K
Filed at:   2025-01-21T23:59:59+00:00
Accession:  0001006837-25-000002
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MediBeacon TGFR System Receives FDA Approval for Kidney Function Assessment
---------------------------------------------------------------------------

- FDA approved MediBeacon Transdermal GFR (tGFR) for assessing kidney function in adults with normal or impaired renal function without input of age, sex, race.
- TGFR uses a non-radioactive fluorescent agent (Lumitrace) with a transdermal sensor; no blood draws or urine analysis needed.
- Primary efficacy endpoint met: P30 value of 94% (95% CI: 89.4%-96.9%) in clinical study across GFR ranges and skin tones.
- More than 800 million people globally have chronic kidney disease; TGFR aims to improve point-of-care assessment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006837/000100683725000002/0001006837-25-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006837/000100683725000002/hchc-20250117.htm
  HTML page:      https://secwatch.observer/filing/0001006837-25-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer